A rapid method for obtaining mesenchymal stem cells and platelets from bone marrow aspirate. (19th June 2012)

• Record Type: Journal Article
• Authors: Dozza, Barbara; Gobbi, Giuliana; Lucarelli, Enrico; Pierini, Michela; Bella, Claudia Di; Frisoni, Tommaso; Tazzari, Pier Luigi; Ricci, Francesca; Mirandola, Prisco; Carubbi, Cecilia; Giannini, Sandro; Donati, Davide; Vitale, Marco
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 8:Number 6(2014:Jun.)
• Page Start: 483
• Page End: 492
• Publication Date: 2012-06-19
• Subjects: Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.1551
• Languages: English
• ISSNs: 1932-6254

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p>Mesenchymal stem cells (MSCs) and platelet‐rich plasma (PRP) are currently used alone or in combination for therapeutic applications especially for bone repair. We tested whether MSCs can be isolated from bone marrow (BM) aspirate using a commercially available kit commonly used to obtain PRP from peripheral blood (PB). Results revealed that mononuclear cells and platelets from both PB and BM could be efficiently isolated by obtaining a mononuclear and platelet rich fraction (PB‐MPRF and BM‐MPRF, respectively). Starting with comparable volumes, the number of platelets increased 1.5‐fold in BM‐MPRF compared to PB‐MPRF. The number of clonogenic cells in BM‐MPRF samples was significantly higher than whole BM samples as revealed by CFU‐F assay (54.92 ± 8.55 CFU‐F/1.5 x 10⁵ nucleated cells and 32.50 ± 12.43 CFU‐F/1.5 x 10⁵ nucleated cells, respectively). Cells isolated from BM‐MPRF after <italic>in vitro</italic> expansion fulfilled the definition of MSCs by phenotypic criteria, and differentiated along osteogenic, adipogenic and chondrogenic lineages following induction. Results showed that the kit isolated MSCs and platelets from BM aspirate. Isolated MSCs were further expanded in a laboratory and BM‐MPRF was used clinically following BM withdrawal for rapid intra‐operative cell therapy for the treatment of bone defects. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p> </abstract>